Tandem Mobi System
SOFTWARE VERSION 7.9
What's New
This software update allows you to use Control-IQ+ technology with your Tandem Mobi system. If you are updating your pump from an earlier software version (version 7.7), you can also now choose your CGM sensor.*
Extended Bolus
The extended bolus can now be set for up to eight hours. Previously it was only available for up to two hours.
Temp Basal Rate
It can now be used while keeping Control-IQ+ on, even when Sleep Activity or Exercise Activity are active.
You must complete the required online training in your Tandem Source platform account before you can initiate the pump software update.
Choose a convenient time when you have supplies on hand and can stop all insulin delivery. You will need to disconnect your infusion set during the update and load a cartridge to resume insulin delivery.
Confirm your eligibility to request a software update†
* CGM sold separately.
† Software updates are only available to customers who have in-warranty pumps at the time they update their software. They may also require a prescription and additional training. Charges may apply. Tandem may discontinue select software and features over time at its discretion.
Important Safety Information
RX ONLY. The Tandem Mobi insulin pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin.
Tandem Mobi system: The Tandem Mobi insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.
Warning: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.